SCIENTIFIC REPORT 2010 - 2011 - IOV

More documents

Recommendations

Info

Mission The mission of this Unit is to provide patient access to new drugs and protocols through participation in major national and international studies. The whole staff is engaged in implementing the culture of quality and research as an added value that allows the activation of Phase I studies. Also, a major commitment is Areas of Excellence The Unit is especially dedicated to the following areas: study of new drugs and translational research in melanoma, lung neoplasms, and hepatocarcinoma; high-dose therapy and peripheral stem cell support in refractory lymphoma, myeloma and lymphomas of the elderly; development of protocols for patients with solid tumors or lymphoproliferative disease after organ transplantation or acquired immunodeficiency; assessment of the role of PET/CT in staging of breast cancer at high risk, in metastatic ocular melanoma, in the staging and restaging of esophageal cancer; Clinical Activity In <strong>2010</strong>, 1358 new patients were seen: the tumors most represented were, in the following order: breast cancer, lung cancer and melanoma, constituting 72% of the total. Two hundred-fifty THE DEPARTMENTS - DEPARTMENT OF CLINICAL ONCOLOGY 48 to provide continuity and quality of care through a rigorous multidisciplinary approach and networking with both regional and extra-regional centers, in order to avoid the need for patients to migrate to gain access to study protocols. study and treatment of breast tumors in patients younger than 35 years; definition of new criteria for evaluation of efficacy and immunomodulatory therapies; definition of new schemes in the combined treatment of head and neck and esophageal cancer; evaluation of risk factors in the development of brain metastases and their treatment; study of systemic and locoregional treatment combination in the treatment of metastatic melanoma. eight patients entered study protocols. Most services were provided in the outpatient setting with 11,626 accesses for treatment and 9,821 for follow-up. The inpatient admissions were 389.
Distribution of patients by cancer site 600 500 400 300 200 100 0 540 Breast 299 Lung 212 Melanoma Major Collaborations Esophagus Lymphoma Inside the <strong>IOV</strong> For all the malignancies (lung, head-and-neck, esophagusstomach, liver, lymphoma, melanoma, breast, endocrine, hepatocellular carcinoma), multidisciplinary weekly meetings are active. Moreover, scientific investigations which involve the dedicated oncologist, the dedicated radiation oncologist, the appropriate surgeon, the radiologist, a nuclear physician, a gastroenterologist endoscopist are also ongoing. Multidisciplinary clinics and meetings are open to all specialists and trainees. National Collaborations Azienda ULSS “Veneziana” (Oncologia Medica) Dipartimento di Scienze Otorino-Odonto-Oftalmologiche-Cervico Facciali (Università degli Studi di Parma) IRCCS - HSR Ospedale San Raffaele (Milano) IRCCS - INT Istituto Nazionale dei Tumori (Milano) IRCCS - CRO Centro Riferimento Oncologico (Aviano) IRCCS - IEO Istituto Europeo di Oncologia (Milano) Azienda Ospedaliero Universitaria “Ospedali Riuniti”- Clinica di Endocrinologia (Ancona) Azienda Ospedaliera S. Croce e Carle - Oncologia Medica (Cuneo) 89 84 Stomach Head & Neck THE DEPARTMENTS - DEPARTMENT OF CLINICAL ONCOLOGY 49 44 52 37 Endocrine 12 Mieloma 7 Post-transplant neoplasms Azienda Ospedaliera “Istituti Ospitalieri”- Chirurgia Generale (Cremona) Gruppo interdisciplinare per lo studio e trattamento dell’epatocarcinoma Gruppo interdisciplinare per lo studio e trattamento dei GIST (“G.I. - GIST”) Gruppo interdisciplinare per lo studio e trattamento dei tumori neuroendocrini (“G.I. - NET”) META (Melanoma Task Force) IMI (Italian Melanoma Intergroup) International Collaborations University Hospital, Zurich, Switzerland (Prof. R. Stahel) Istituto Oncologico Catalano, Barcelona, Spain (Prof. R. Rosell) Theaghenion Anticancer Hospital - Salonicco (Greece) EORTC Melanoma Group EORTC EBMT (European Bone Marrow Transplantation Group) ECOG (East Cooperative Oncology Group) Melanoma Group GMGT (Global Melanoma Task Force)
Page 1: SCIENTIFIC REPORT 2010 - 2011 ISTIT
Page 4 and 5: Line 5 - Tumor Immunology and Innov
Page 6 and 7: This volume is the third edition of
Page 9 and 10: THE INSTITUTE THE INSTITUTE 9
Page 11 and 12: Aerial view of the Busonera area TH
Page 13 and 14: Chief Officer Address THE INSTITUTE
Page 16 and 17: The IOV Governance The IOV is gover
Page 18 and 19: GENERAL DIRECTORATE Pier Carlo Muzz
Page 21 and 22: Chief Medical Officer Report CLINIC
Page 23 and 24: to interact with other IRCCS to pro
Page 25 and 26: DRG average relative weight 4,5 4,0
Page 27 and 28: Radiation treatments 1200 1000 800
Page 29 and 30: The experts of these groups meet at
Page 31 and 32: THE DEPARTMENTS THE DEPARTMENTS 31
Page 33 and 34: Department of Clinical Oncology THE
Page 35 and 36: Clinical and Research Staff Vittori
Page 37 and 38: Clinical Activity Distribution of p
Page 39 and 40: Major Ongoing Research Projects NEw
Page 41 and 42: of Ramucirumab using a double-blind
Page 43: events has been planned in order to
Page 46 and 47: Main Pubblications Clinical Oncolog
Page 50 and 51: Major Ongoing Research Projects iDE
Page 52: NEw ThErapEuTiC STraTEGiES iN ThE T
Page 55 and 56: Clinical and Research Staff Antonio
Page 57 and 58: Department of Surgery THE DEPARTMEN
Page 59 and 60: Clinical and Research Staff Carlo C
Page 61 and 62: Major Research Collaborations Insid
Page 64 and 65: Main Pubblications Chief Breast Sur
Page 66 and 67: Mission The mission of the Breast S
Page 68 and 69: Main Pubblications Melanoma and Sof
Page 70 and 71: Mission The Melanoma and Soft Tissu
Page 72 and 73: National Collaborations Italian Sar
Page 74 and 75: express bioluminescent or fluoresce
Page 76 and 77: Diagnostic and Operative Endoscopy
Page 78 and 79: Mission The mission of the Unit is
Page 80 and 81: Major Ongoing Research Projects frO
Page 82 and 83: Main Pubblications Chief Comparison
Page 85 and 86: Mission The mission of the Unit of
Page 87 and 88: late (occurring after the first che
Page 89 and 90: Department of Imaging, Radiology &
Page 91 and 92: Clinical and Research Staff Fabio P
Page 93 and 94: Major Ongoing Research Projects Dif
Page 96 and 97: Main Pubblications Chief Correlatio
Page 98 and 99:
Mission The Breast Imaging Unit mis
Page 100 and 101:
Regarding the new HIBRC2 study, the
Page 102 and 103:
Methods. Patient accrual, following
Page 104 and 105:
Mission and Clinical Activity The m
Page 107 and 108:
Department of Radiotherapy & Nuclea
Page 109 and 110:
Clinical and Research Staff Guido S
Page 111 and 112:
Clinical Activity The acquisition o
Page 113 and 114:
Areas of Excellence Thyroid cancer
Page 115 and 116:
Fig. 2. The thick Beryllium target,
Page 117 and 118:
field and the Nuclear Medicine Serv
Page 120 and 121:
Main Pubblications Chief Medical Ph
Page 122 and 123:
Mission To assure safe, accurate an
Page 124 and 125:
Other Programs and Future Perspecti
Page 127 and 128:
Department of Experimental, Laborat
Page 129 and 130:
Clinical and Research Staff Annaros
Page 131 and 132:
Analyses for solid tumors by year A
Page 133 and 134:
egard, the activity of some researc
Page 135 and 136:
to high-risk families; b) assessmen
Page 137 and 138:
with plasmids expressing either p16
Page 139 and 140:
The results published so far indica
Page 141 and 142:
levels of h-TERT mRNA increased wit
Page 143 and 144:
More recently, given that the real
Page 145 and 146:
aDvaNCED appliCaTiONS Of CirCulaTiN
Page 147 and 148:
the persistence of more aggressive
Page 149 and 150:
phosphokinome will be investigated
Page 151 and 152:
algorithm that takes into account t
Page 153 and 154:
samples. Except for 13q deletions,
Page 155 and 156:
Clinical and Research Staff Giusepp
Page 157 and 158:
Figure 1. the tumor of the adrenal
Page 159 and 160:
goal of this project is to use a co
Page 161 and 162:
Department of Services THE DEPARTME
Page 163 and 164:
Clinical and Research Staff Angelo
Page 165 and 166:
according to the onco-AIFA Registry
Page 168 and 169:
Main Pubblications Chief Alberto Ba
Page 170 and 171:
Mission This Unit is mainly devoted
Page 172 and 173:
Main Pubblications Chief Positive e
Page 174 and 175:
Mission The Psycho-oncology Service
Page 176 and 177:
An ad hoc intervention has therefor
Page 178 and 179:
Main Pubblications Chief Cancer pre
Page 180 and 181:
Mission The main aims of the Veneto
Page 182:
Population and Social Policies. Thi
Page 187 and 188:
Scientific Director Address THE RES
Page 189 and 190:
e transferred from the bench to bed
Page 191 and 192:
Scientific Directorate Organization
Page 193 and 194:
library Responsible: Mauro Apostoli
Page 195 and 196:
In the awareness of the difficult t
Page 197 and 198:
Research: Input and Output The rese
Page 199 and 200:
strategic focus for the Government
Page 201 and 202:
Impact Factor Trend 1000 800 600 40
Page 203 and 204:
Clinical and Research Staff Gian Lu
Page 205 and 206:
International Collaborations Emma C
Page 209 and 210:
Strategic Scientific Options THE RE
Page 211 and 212:
approaches are tested at the IOV wi
Page 213 and 214:
Thiopurine S-methyltransferase (TPM
Page 215 and 216:
of specific functional features of
Page 217 and 218:
RESEARCH ACTIVITY REPORT RESEARCH A
Page 219 and 220:
N° Prog Titolo Responsabile L01P01
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
L03P44 L03P45 L03P46 L03P47 L03P48
Page 227 and 228:
Page 229 and 230:
L04P39 Chemioterapia adiuvante in p
Page 231 and 232:
Page 233 and 234:
Progr. Titolo Responsabile L06P01 L
Page 235 and 236:
CLINICAL RESEARCH CLINICAL RESEARCH
Page 237 and 238:
Numerous phase II and III, sponsore
Page 239 and 240:
A Multicenter phase III trial to ev
Page 241 and 242:
LUNG An International multicenter r
Page 243:
A randomized, double-blind, placebo
Page 246 and 247:
Veneto Oncology Network The Istitut
Page 248 and 249:
Building a network is not a trivial
Page 250 and 251:
Internal Education & Training The I
Page 252 and 253:
La comunicazione interpersonale neg
Page 254 and 255:
Trattamento del dolore cronico nel
Page 256 and 257:
EDUCATION 256
Page 258 and 259:
Charles R M Bangham How does HTLV-1
Page 261:
AWARDS VENETO ONCOLOGY AWARDS NETWO
Page 265 and 266:
PUBLICATIONS PUBLICATIONS 265
Page 267 and 268:
carcinoma with singular bone metast
Page 269 and 270:
46 Ciccolallo L, Licitra L, Cantù
Page 271 and 272:
P, Rubeca T, Zappa M. Immunochemica
Page 273 and 274:
113 Novara G, De Marco V, Aragona M
Page 275 and 276:
4-mercaptophenol derivative designe
Page 277 and 278:
Use of a manual dermatoscope with a
Page 279 and 280:
Cancer Genetics Network, Thomassen
Page 281 and 282:
33 Cecchin D, Schiavi F, Fanti S, F
Page 283 and 284:
of diphtheria toxin A or its varian
Page 285 and 286:
17:3; 524-528; 2010 95 Lumachi F, L
Page 287 and 288:
130 Peranzoni E, Zilio S, Marigo I,
Page 289 and 290:
Surgery of the Alimentary Tract; 14
Page 291 and 292:
191 Zorzi M, Baracco S, Fedato C. L
Page 293 and 294:
ectal cancer: Pathologic results of
Page 295 and 296:
[as member of AIRTUM WG: Zambon P,
Page 297 and 298:
in laryngeal carcinoma treated with
Page 299 and 300:
G, Toland A E, Gerdes A M, Thomasse
Page 301 and 302:
european patients with central nerv
Page 303:
2011 PUBLICATIONS / Non indexed in
Page 306 and 307:
Index of Names A Alaibac Mauro 46,
Page 308 and 309:
Analytical Index A Acute Lymphoblas
Page 310:
Colophon Title: Scientific Report 2
show all

SCIENTIFIC REPORT 2010 - 2011 - IOV

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?